Business Wire

Acute Bacterial Skin and Skin Structure Infections Global Market Report 2022: Acquisition of Drug Distribution Rights A Key Growth Factor - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Acute Bacterial Skin and Skin Structure Infections Market, by Drug Type, by Infection Type, by Route of Administration, by Distribution Channel, and by Region - Size, ...
Medscape

Resistant Pathogen-associated Skin and Skin-structure Infections: Antibiotic Options

Simple, uncomplicated SSSIs include erysipelas, cellulitis, furuncles, superficial abscesses and wound infections, whereas deeper complicated SSSIs (cSSSIs) include necrotizing fasciitis, myositis and ...
The Globe and Mail

Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market: Insights into Epidemiology, Treatments, and Key Companies | MicuRx, Basilea Pharmaceuticals, AbbVie, Cubist ...

As per secondary analysis, ABSSSI accounted for almost 870,000 hospital admissions in the United States in 2004 which represents an increase of almost 30% in the incidence of this diagnosis over a ...

Fresenius Kabi Introduces Dalbavancin for Injection (for single-dose regimen use only)

Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical ...
Monthly Prescribing Reference

Kimyrsa Now Available for Acute Bacterial Skin/Skin Structure Infections

Kimyrsa is a single-dose, long-acting lipoglycopeptide antibiotic. Kimyrsa™ (oritavancin) is now available for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) ...
FierceBiotech

Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

CHICAGO -- Durata Therapeutics, Inc. (Nasdaq:DRTX), an emerging specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug ...
Welltica+ on MSN

The new skin infection spreading across the UK faster than doctors expected

Hospitals in the UK and Ireland have seen infections rise from just a few dozen cases before 2022 to well over 250 this year, ...
JSTOR Daily

Omadacycline for Acute Bacterial Skin and Skin Structure Infections

Fredrick M. Abrahamian, George Sakoulas, Evan Tzanis, Amy Manley, Judith Steenbergen, Anita F. Das, Paul B. Eckburg, Paul C. McGovern Clinical Infectious Diseases ...
Business Wire

Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S.
JSTOR Daily

Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study

Background. Oritavancin is a lipoglycopeptide antibiotic with rapid bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and long half-life allow for single-dose ...
Mena FN

Acute Bacterial Skin And Skin-Structure Infection (ABSSSI) Market: Insights Into Epidemiology, Treatments, And Key Companies Micurx, Basilea Pharmaceuticals, Abbvie, Cubist ...

"Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market"As per secondary analysis, ABSSSI accounted for almost 870,000 hospital admissions in the United States in 2004 which represents an ...
Monthly Prescribing Reference

Kimyrsa Approved for Acute Bacterial Skin/Skin Structure Infections

First Global Report on Antibiotic Resistance Both Kimyrsa and Orbactiv are oritavancin products indicated for acute bacterial skin and skin structure infections. The Food and Drug Administration (FDA) ...